Delic Holdings Shares Corporate Updates: Revenues Grow As Ketamine Clinic Chain Continues Expansion

Delic Holdings Shares Corporate Updates: Revenues Grow As Ketamine Clinic Chain Continues Expansion

Delic Holdings Corp. DELCF owns and operates an umbrella of psychedelics-related businesses towards improving access to health benefits across the U.S., including one of the largest chain of psychedelic wellness clinics in the country, Ketamine Wellness Centers (KWC). 

Besides the KWC, Delic holds the only licensed entity by Health Canada to exclusively focus on R&D of psilocybin vaporization technology, Delic Labs; a psychedelic wellness event company called Meet Delic; as well as media and e-commerce platforms Reality Sandwich and Delic Radio. The holding company’s team involves industry and cannabis veterans and a diverse network with the mission to provide education, research, high-quality products and effective treatment options for those in need.

The company announced several corporate updates. First, it released its first annual earnings report, which showed that in 2021 Delic generated more than $1.5MM in revenue and increased net assets to $10MM from its $2.1MM in 2020.

It also announced that the KWC, currently operating in 13 clinics accepting insurance, is now approaching 100,000 treatments to clinically eligible patients. It has settled a new partnership with the Veterans Administration (VA) in Arizona in addition to the VA partnership in Minnesota, launched the Ketamine Wellness Integrative Therapist Directory to connect patients with qualified mental health practitioners.

The ketamine clinics have officially begun to offer FDA-approved esketamine nasal spray Sparavato as of April 1 in Houston, Las Vegas and Seattle while treatment is expanding to the Minneapolis, Salt Lake City and Dallas clinics. 

Furthermore, KWC has introduced "NAD+" infusion therapy as a treatment option at six of its locations: Jacksonville, Houston, Salt Lake City, Dallas, Las Vegas and Tucson, and plans to expand nationwide. The therapy is administered intravenously or intramuscularly, and the company says it has the potential to "boost natural energy stores and immunity, brain and DNA function and cell communication, along with enhancing the process of healing chronic conditions such as depression, PTSD and anxiety."

Facing the announcements, the company’s co-founder and CEO Matt Stang is optimistic: "I'm very excited to say Delic Corp is thriving and continuing to grow as evidenced by the revenue we generated in our first full year of operation. We have a strong team across all the businesses and I'm proud of the work we have done so far to make these life-changing therapies more affordable and accessible, while also working to change the perception of psychedelics and mental health.” 

Stang furthermore added: “However, there are still too many people suffering with mental health conditions who are not aware of the help available to them right now. We will continue to find solutions to these challenges and make sure the treatments are more affordable and everyone who needs these therapies has access to them."

Photo by armando pacheco on Unsplash

Posted In: Delic LabsKWCMatt StangNAD+ infusion therapySpravatoCannabisNewsPenny StocksPsychedelicsManagementMarkets

BENZINGA CANNABIS CONFERENCE

Meet the biggest cannabis industry players and make deals that will push the industry forward.

Featuring live company presentations, insider panels, and unmatched access to networking, the Benzinga Cannabis Capital Conference is where cannabis executives and entrepreneurs meet.

Join us September 13-14, 2022 at The Palmer House in Chicago, IL.